The Healthcare Technology Report has named ELEGEN among the Top 100 Healthcare Technology Companies of 2024! We’re honored to be included alongside innovative healthcare technology leaders who are driving the industry forward. Congratulations to all the companies featured this year!? Check out the full list: https://hubs.ly/Q02Y_6yH0 #DNAinnovation #biotech #genesynthesis
ELEGEN
生物技术
San Carlos，California 5,506 位关注者
Unlock the promise of synthetic biology by accelerating the Design-Build-Test-Learn cycle
关于我们
We are now at the dawn of the synthetic biology revolution, which will spawn new applications, markets, and business models, improving human lives in countless ways. This revolution will be driven by new technologies that enable DNA writing at speed and scale. To catalyze this revolution, Elegen is creating a suite of ground-breaking technologies to achieve DNA writing with unparalleled speed, cost, and quality. Elegen is unlocking the power to reprogram biology and create biologic solutions in order to solve some of humanity’s greatest challenges. Founded and led by Dr. Matthew Hill and located in San Carlos, CA, Elegen is a stealth-mode company that is well capitalized by top life science investors, including Andreessen Horowitz, 8VC, and KdT. The company is advised and staffed by leading biotechnology scientists and entrepreneurs, including Dr. Marc Unger, inventor of the Nanoflex? valve and former CSO of Fluidigm. Dr. Hill has a PhD from Stanford and a proven track record of advancing innovative technologies from invention to commercial success.
- 网站
-
https://www.elegenbio.com
ELEGEN的外部链接
- 所属行业
- 生物技术
- 规模
- 51-200 人
- 总部
- San Carlos，California
- 类型
- 私人持股
- 创立
- 2017
- 领域
- microfluidics、hardware、synthetic biology、engineering、organic chemsitry、DNA Synthesis、molecular biology和biology
地点
-
主要
获取路线
1300 Industrial Rd
US，California，San Carlos，94070
ELEGEN员工
动态
-
Webinar TOMORROW! There’s still time to register for the free Cell & Gene Therapy Showcase highlighting innovative tools and technologies in #CGT discovery and sponsored by ELEGEN, Applied StemCell, Benchling and Sartorius. See you there! Learn more: https://hubs.ly/Q02YV6p-0 #CGT #GeneTherapy #GeneSynthesis #NextGenDNA?#CellFreeCloning
-
-
ELEGEN转发了
Have you registered for Thursday's Showcase?
Cell & Gene Therapy Showcase Join the DDW Cell & Gene Therapy Showcase, a free online event hosted by DDW and co-sponsored by Benchling, Sartorius, Applied StemCell, and ELEGEN Bio. In this free online event leading industry figures will outline areas of opportunity in CGT drug discovery & development sector as well as highlighting challenges facing the industry and how they can be overcome. It will feature presentations from experts in the field of cell and gene therapy drug development as well as a panel discussion.? Presentations will cover areas such as the complexities of an unclear and rapidly evolving regulatory framework for cell and gene therapies, offering examples of how to navigate the investigational new drug (IND) submission process. They will also cover how next-generation gene synthesis technology is helping to advance areas such as TCR engineering, CAR-T therapies, gene editing, and mRNA vaccines. In addition, sponsors will be given the opportunity to present their technology to the DDW audience. The panel discussion will cover areas including:? ? Making use of new drug discovery and development technology, concepts and tools in CGT?? ? What will the future of innovative CGT therapies be and how to plan now for opportunity??? ? Where are the global CGT hotspots for research, funding and clinical trials? Thu, Nov 21, 2024 2:00 PM - 3:00 PM GMT Register for free now to secure your place! https://lnkd.in/ee8DZBRU #CellTherapy #GeneTherapy #CGT
-
-
We’re honored to announce that we won the 2024 BioTech Breakthrough “DNA Synthesis ??Technology of the Year” Award! ?? It’s been a banner year of making headway on our cell-free ENFINIA DNA: long, high complexity, NGS-verified gene synthesis that eliminates cloning to accelerate #geneticmedicine discovery. Way to go, #TeamElegen! ?? Congrats to all winners! ??Read more: https://hubs.ly/Q02YJGXF0 #GeneticMedicine #GeneSynthesis #DNASynthesis #TechnologyoftheYear #DNAInnovation #CellFreeCloning
-
We continue to grow! Join #TeamElegen as we innovate programmable biology–our employees consistently rank the company camaraderie & culture as favorite factors in their work (see https://hubs.ly/Q02Yq_Bt0)!? Check out our openings:? https://hubs.ly/Q02YqTj80 #biotech #SanFrancisco #BayAreaJobs #programmablebiology #DNAinnovation
-
-
ELEGEN转发了
Cell & Gene Therapy Showcase Join the DDW Cell & Gene Therapy Showcase, a free online event hosted by DDW and co-sponsored by Benchling, Sartorius, Applied StemCell, and ELEGEN Bio. In this free online event leading industry figures will outline areas of opportunity in CGT drug discovery & development sector as well as highlighting challenges facing the industry and how they can be overcome. It will feature presentations from experts in the field of cell and gene therapy drug development as well as a panel discussion.? Presentations will cover areas such as the complexities of an unclear and rapidly evolving regulatory framework for cell and gene therapies, offering examples of how to navigate the investigational new drug (IND) submission process. They will also cover how next-generation gene synthesis technology is helping to advance areas such as TCR engineering, CAR-T therapies, gene editing, and mRNA vaccines. In addition, sponsors will be given the opportunity to present their technology to the DDW audience. The panel discussion will cover areas including:? ? Making use of new drug discovery and development technology, concepts and tools in CGT?? ? What will the future of innovative CGT therapies be and how to plan now for opportunity??? ? Where are the global CGT hotspots for research, funding and clinical trials? Thu, Nov 21, 2024 2:00 PM - 3:00 PM GMT Register for free now to secure your place! https://lnkd.in/ee8DZBRU #CellTherapy #GeneTherapy #CGT
-
-
Interesting post and C&EN reporting on endotoxin testing, which conventionally has relied on horseshoe crab blood to produce a high-sensitivity reagent called limulus amoebocyte lysate (LAL). New animal-free recombinant tests have been approved by the US Pharmacopeia and are expected to go into effect in May 2025. Using Plasmid DNA as a template for IVT-mediated mRNA synthesis requires rigorous endotoxin testing to ensure that contaminants from bacteria used in the cloning process are removed before downstream use. In contrast, ELEGEN’s next-gen #genesynthesis is cell-free, completely eliminating cloning and the risk of contaminants such as endotoxins, mycoplasma, and residual genomic DNA to enable an efficient and more environmentally friendly workflow. Learn more: https://bit.ly/44arKb0 #cellfreecloning #dnasynthesis #dnainnovation
No crabs were harmed in the making of this post; but millions have died for the sake of biotech. The endotoxin testing market is worth about $1B annually in the US alone. Any substance or medical device going into a patient or animal has to be tested for endotoxin to ensure there are no trace amounts of glycolipid from the surface of bacteria. Unfortunately for the horseshoe crab their blue colored blood contains a sensitive biosensor that enables simple detection of endotoxin. This was first discovered in 1964 and the first endotoxin tests using LAL from horseshoe crabs was approved by the FDA in 1977. Fast forward to today and almost a million crabs are collected in the US each year. They are bled and then released but up to 30% later die and those that survive may not be healthy enough to spawn. It's difficult to imagine the biotech industry without these simple and accurate endotoxin tests. For decades it has been a necessary evil. But it might surprise you to learn that an animal free recombinant version of the critical protein was developed as far back as 1995. This was then commercialized by Lonza in 2003 but still to this day recombinant based endotoxin tests haven’t really taken off. In the EU these recombinant tests were officially recognized in 2015 and in China this occurred in 2020 but the US has lagged behind. The small number of producers of horseshoe crab based tests dominate the market and potentially have a lot to lose with a wholesale switch to recombinant. There have been many false dawns in the fight to save the horse shoe crabs from unnecessary harm but finally we might be at a real turning point. In November, US regulators will formally announce the acceptance of recombinant alternatives for endotoxin testing, which should then come into effect in May 2025. Laurel Oldach at Chemical and Engineering News has written an excellent article on this topic. I highly recommend reading it if you want to learn more about the long drawn-out fight to get these tests accepted. https://lnkd.in/eaG2QvEi ----- I'm Ian, I post about antibody engineering, recombinant proteins and my journey to bootstrap Gamma Proteins into a leading supplier of Fc receptors. If you like my content please reshare with your network and follow me to see more.
-
-
IVT mRNA technologies are showing great promise as next-gen therapeutics, though there remain questions about the effect of impurities that can occur during the #IVT reactions re: the functionality and stability of the mRNA. Great step forward by Julien Camperi, Axel Guilbaud and the Genentech team on developing highly sensitive and advanced methods to characterize these IVT mRNA impurities to ensure quality control of RNA-based therapies! One method studied PolyA tail length on IVT, showing a positive correlation of IVT efficiency between longer tails (160 nt) and protein expression. ELEGEN's cell-free #GeneSynthesis supported & accelerated this study with a supply of long, NGS-verified, complex ENFINIA DNA shipped within a week. Read the #AnalyticalChemistry (American Chemical Society) paper: https://bit.ly/4hZslmq #CellFreeCloning #DNAinnovation #mRNAtherapies #LongDNA #IVTReadyDNA #NextGenDN
-
This month we spotlight a valuable member of our Production team, Bemesgana (Mesgana) Alemu! Mesgana loves the broad reach of the biotech industry, as there are so many subfields that align with her personal interests. We ?? that she chose to work on #TeamElegen. We're #LuckyToHaveYou! Learn more about Mesgana: https://bit.ly/3AAWac6 #EmployeeSpotlight #Hiring? #BayAreaJobs #SanFrancisco
-
-
Looking for a leading edge in cell & gene therapy development? Innovative next-gen technologies will be presented in this free webinar, hosted by Drug Discovery World, Nov 21 at 9am EST. Register: https://bit.ly/3O56v3c #GeneSynthesis #NextGenDNA #CGT #GeneTherapy #cellfreecloning
-